قالب وردپرس درنا توس
Home / Business / Fauci: The U.S. may not even need AstraZeneca’s COVID-19 vaccine

Fauci: The U.S. may not even need AstraZeneca’s COVID-19 vaccine



Dr. Anthony Fauci said on Thursday that even if the vaccine is approved by federal regulatory agencies, the United States may not need AstraZeneca’s coronavirus vaccine.

In an interview with Reuters, White House Chief Medical Adviser Fauci said that the United States has signed enough contracts with other vaccine manufacturers to vaccinate the entire population.

He said: “My overall feeling is that, given our contractual relationship with multiple companies, we have enough vaccines to meet all our needs without having to call AstraZeneca.”

What we know about the AstraZeneca vaccine blood clot report

The nation’s largest infectious disease expert added that the United States may also have enough vaccine supplies for booster injections in the fall.

He told Reuters: “If you look at the amount (dose) we are going to get… It̵

7;s likely that we can handle any boost needed, but I can’t say for sure.”

Once hailed as a breakthrough in the fight against COVID-19, AstraZeneca’s shooting has been under scrutiny since the second half of last year.

Dr. Anthony Fucci, Director of the National Institute of Allergy and Infectious Diseases and Chief Medical Adviser to the President, speaks with a group of clergy, community leaders and officials of different faiths at the National Cathedral in Washington to encourage faith communities to obtain COVID vaccines, March 2021 Tuesday, the 16th, Washington.  (AP Photo/Manuel Balce Ceneta)

Dr. Anthony Fucci, Director of the National Institute of Allergy and Infectious Diseases and Chief Medical Adviser to the President, speaks with a group of clergy, community leaders and officials of different faiths at the National Cathedral in Washington to encourage faith communities to obtain COVID vaccines, March 2021 Tuesday, the 16th, Washington. (AP Photo/Manuel Balce Ceneta)

Last month, more than a dozen countries approved the London-based pharmaceutical company’s VAX device because of reports that the product was related to a rare blood clotting disorder, so its use was temporarily suspended.

At the same time, US regulators accused the company of providing “cherry picking” data to make it look more effective.

After public criticism, AstraZeneca stated that the data was based on a “pre-designated provisional analysis” and agreed to publish an updated report.

The company subsequently released the revised results, showing that its inoculation efficacy is weak but still strong.

Click here for the FOX News App

AstraZeneca also stated that it intends to seek emergency use authorization from the FDA for the vaccine within a few weeks.


Source link